JP2003513664A - ヒト胚性幹細胞の造血分化 - Google Patents
ヒト胚性幹細胞の造血分化Info
- Publication number
- JP2003513664A JP2003513664A JP2001537473A JP2001537473A JP2003513664A JP 2003513664 A JP2003513664 A JP 2003513664A JP 2001537473 A JP2001537473 A JP 2001537473A JP 2001537473 A JP2001537473 A JP 2001537473A JP 2003513664 A JP2003513664 A JP 2003513664A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hematopoietic
- human
- cell
- embryonic stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001671 embryonic stem cell Anatomy 0.000 title claims abstract description 24
- 230000003394 haemopoietic effect Effects 0.000 title claims description 17
- 230000004069 differentiation Effects 0.000 title description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000004113 cell culture Methods 0.000 claims abstract description 14
- 210000002536 stromal cell Anatomy 0.000 claims abstract description 14
- 230000001332 colony forming effect Effects 0.000 claims description 15
- 210000004248 oligodendroglia Anatomy 0.000 claims description 8
- 229920000609 methyl cellulose Polymers 0.000 claims description 7
- 239000001923 methylcellulose Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
- 210000002798 bone marrow cell Anatomy 0.000 claims description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 claims 1
- 210000004170 yolk cell Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 11
- 238000001802 infusion Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 118
- 239000001963 growth medium Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 15
- 210000001185 bone marrow Anatomy 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 210000001325 yolk sac Anatomy 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 102100033779 Collagen alpha-4(IV) chain Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101000710870 Homo sapiens Collagen alpha-4(IV) chain Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 101100219325 Phaseolus vulgaris BA13 gene Proteins 0.000 description 1
- 241000705082 Sialia Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000002791 cfu-m Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/435,578 | 1999-11-08 | ||
| US09/435,578 US6280718B1 (en) | 1999-11-08 | 1999-11-08 | Hematopoietic differentiation of human pluripotent embryonic stem cells |
| PCT/US2000/023469 WO2001034776A1 (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009229464A Division JP2010042011A (ja) | 1999-11-08 | 2009-10-01 | ヒト胚性幹細胞の造血分化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003513664A true JP2003513664A (ja) | 2003-04-15 |
| JP2003513664A5 JP2003513664A5 (enExample) | 2007-10-11 |
Family
ID=23728955
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001537473A Pending JP2003513664A (ja) | 1999-11-08 | 2000-08-25 | ヒト胚性幹細胞の造血分化 |
| JP2009229464A Pending JP2010042011A (ja) | 1999-11-08 | 2009-10-01 | ヒト胚性幹細胞の造血分化 |
| JP2013210318A Pending JP2014000096A (ja) | 1999-11-08 | 2013-10-07 | ヒト胚性幹細胞の造血分化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009229464A Pending JP2010042011A (ja) | 1999-11-08 | 2009-10-01 | ヒト胚性幹細胞の造血分化 |
| JP2013210318A Pending JP2014000096A (ja) | 1999-11-08 | 2013-10-07 | ヒト胚性幹細胞の造血分化 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6280718B1 (enExample) |
| EP (1) | EP1228194A1 (enExample) |
| JP (3) | JP2003513664A (enExample) |
| KR (2) | KR20030022766A (enExample) |
| CN (1) | CN1228443C (enExample) |
| AU (1) | AU784928B2 (enExample) |
| BR (1) | BR0015374A (enExample) |
| CA (1) | CA2390281C (enExample) |
| IL (2) | IL149387A0 (enExample) |
| IS (1) | IS6373A (enExample) |
| NO (1) | NO20022180L (enExample) |
| SE (1) | SE526490C2 (enExample) |
| WO (1) | WO2001034776A1 (enExample) |
Families Citing this family (191)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| JP2002529070A (ja) * | 1998-11-09 | 2002-09-10 | モナシュ・ユニヴァーシティ | 胚性幹細胞 |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
| US20030129745A1 (en) * | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
| US6602711B1 (en) * | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
| US6607720B1 (en) | 2000-09-05 | 2003-08-19 | Yong-Fu Xiao | Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
| US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
| EP2305795B1 (en) | 2000-12-06 | 2019-07-03 | Celularity, Inc. | Method of collecting placental stem cells |
| US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| CA2435826A1 (en) * | 2001-01-24 | 2002-08-01 | The Government Of The United States Of America | Differentiation of stem cells to pancreatic endocrine cells |
| JP2004529621A (ja) * | 2001-02-14 | 2004-09-30 | ティー ファークト，レオ | 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞 |
| WO2002064755A2 (en) * | 2001-02-14 | 2002-08-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| US20030211605A1 (en) * | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
| JP5479661B2 (ja) * | 2001-07-24 | 2014-04-23 | イーエス・セル・インターナショナル・ピーティーイー・リミテッド | 幹細胞の分化を誘導する方法 |
| EP1444326A4 (en) * | 2001-08-24 | 2006-06-28 | Advanced Cell Tech Inc | SCREENING ASSAYS FOR IDENTIFICATION OF AGENTS INDUCING DIFFERENTIATION, AND PRODUCTION OF CELLS DIFFERENTIATED FOR CELL THERAPY |
| DE10144326B4 (de) * | 2001-09-10 | 2005-09-22 | Siemens Ag | Verfahren und System zur Überwachung eines Reifenluftdrucks |
| US6759244B2 (en) * | 2001-11-08 | 2004-07-06 | Art Institute Of New York And New Jersey, Inc. | Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos |
| AU2002356935A1 (en) * | 2001-11-09 | 2003-05-19 | Artecel Sciences, Inc. | Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
| US7799324B2 (en) * | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
| AU2012258384B2 (en) * | 2001-12-07 | 2016-04-21 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
| AU2016206280B2 (en) * | 2001-12-07 | 2018-05-17 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
| US20040224403A1 (en) * | 2001-12-07 | 2004-11-11 | Robarts Research Institute | Reconstituting hematopoietic cell function using human embryonic stem cells |
| GB2399572B (en) * | 2001-12-07 | 2006-06-07 | Robarts Res Inst | Hematopoietic cells from human embryonic stem cells |
| US20030217374A1 (en) * | 2002-01-15 | 2003-11-20 | Advanced Cell Technology | Cloning B and T lymphocytes |
| US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
| US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
| US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
| EP1490478A4 (en) * | 2002-03-18 | 2006-03-22 | Nat Jewish Med & Res Center | PROCESS FOR PRODUCING NEUTROPHILES AND USES THEREOF |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| GB0210741D0 (en) * | 2002-05-10 | 2002-06-19 | Medical Res Council | Methods of therapy |
| US20040091936A1 (en) | 2002-05-24 | 2004-05-13 | Michael West | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
| AU2003237257A1 (en) | 2002-05-24 | 2003-12-12 | Advanced Cell Technology, Inc. | A bank of stem cells for transplantation |
| WO2003102151A2 (en) * | 2002-05-30 | 2003-12-11 | Celgene Corporation | Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors |
| EP1534068A4 (en) * | 2002-08-08 | 2006-08-23 | Univ Georgia Res Found | COMPOSITIONS AND METHODS FOR NEURONAL DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
| WO2004035748A2 (en) * | 2002-10-16 | 2004-04-29 | Advanced Cell Technology, Inc. | Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells |
| GB0224415D0 (en) * | 2002-10-21 | 2002-11-27 | Medical Res Council | Compositions |
| CA2505534A1 (en) | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| WO2004050827A2 (en) * | 2002-12-05 | 2004-06-17 | Technion Research & Development Foundation Ltd. | Cultured human pancreatic islets, and uses thereof |
| US20040110286A1 (en) * | 2002-12-06 | 2004-06-10 | The John P. Robarts Research Institute | Method for making hematopoietic cells |
| BRPI0407427A (pt) * | 2003-02-13 | 2006-01-24 | Anthrogenesis Corp | Método para tratar um paciente e para tratar a mielodisplasia |
| WO2004085616A2 (en) * | 2003-03-24 | 2004-10-07 | The Uab Research Foundation | Regulation of self-renewal in stem cells |
| AU2004227204B2 (en) | 2003-04-08 | 2010-06-03 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to SDF-1 and methods of generating and using same |
| FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
| JP2007535486A (ja) * | 2003-05-07 | 2007-12-06 | ラ ホーヤ インスティチュート フォー モレキュラー メディシン | 高分子量のヒアルロン酸を用いた内因性又は埋め込まれた又は移植された幹細胞の機能回復を促進するための方法 |
| NZ547105A (en) * | 2003-10-16 | 2009-02-28 | Univ Edinburgh | Control of ES cell self-renewal and lineage specification, and medium therefor |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| AU2004291559B2 (en) * | 2003-11-19 | 2008-10-16 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
| US20070269412A1 (en) * | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
| ES2579804T3 (es) * | 2003-12-02 | 2016-08-16 | Celavie Biosciences, Llc | Composiciones y métodos para la propagación de células progenitoras neurales |
| US20070298453A1 (en) * | 2004-02-12 | 2007-12-27 | University Of Newcastle Upon Tyne | Stem Cells |
| US20050232905A1 (en) * | 2004-03-26 | 2005-10-20 | Yeh Edward T | Use of peripheral blood cells for cardiac regeneration |
| WO2005097979A2 (en) * | 2004-03-31 | 2005-10-20 | Newlink Genetics Corporation | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof |
| CN101080486B (zh) * | 2004-04-23 | 2012-05-16 | 佰欧益股份有限公司 | 多谱系祖细胞 |
| US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
| WO2005113751A1 (en) | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Cell culture environments for the serum-free expansion of mesenchymal stem cells |
| EP1809739B1 (en) | 2004-07-13 | 2014-10-15 | Asterias Biotherapeutics, Inc. | Medium for growing human embryonic stem cells |
| CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| WO2006040763A2 (en) * | 2004-10-12 | 2006-04-20 | Technion Research & Development Foundation Ltd. | Isolated primate embryonic cells and methods of generating and using same |
| US20070077654A1 (en) * | 2004-11-01 | 2007-04-05 | Thomson James A | Platelets from stem cells |
| US20060099198A1 (en) * | 2004-11-01 | 2006-05-11 | Thomson James A | Platelets from stem cells |
| EP1844139A1 (en) * | 2004-12-30 | 2007-10-17 | Stemlifeline, Inc. | Methods and systems relating to embryonic stem cell lines |
| US20060275899A1 (en) * | 2004-12-30 | 2006-12-07 | Stemlifeline, Inc. | Methods and compositions relating to embryonic stem cell lines |
| EP1856248A4 (en) * | 2005-02-09 | 2010-01-20 | Burnham Inst Medical Research | HOMOGENEOUS NEURALE CURRENT CELLS |
| CA2607060A1 (en) | 2005-05-04 | 2006-11-09 | Australian Stem Cell Centre Limited | Selecting, culturing and creating lineage committed hematopoietic stem cells |
| US8034613B2 (en) * | 2005-06-01 | 2011-10-11 | Wisconsin Alumni Research Foundation | Multipotent lymphohematopoietic progenitor cells |
| GB2440494B (en) * | 2005-06-01 | 2010-07-28 | Wisconsin Alumni Res Found | Method of forming dendritic from embryonic stem cells |
| WO2007002136A2 (en) | 2005-06-22 | 2007-01-04 | Geron Corporation | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
| CN101233226B (zh) * | 2005-06-22 | 2017-08-11 | 阿斯特利亚斯生物治疗股份公司 | 人胚胎干细胞的悬浮培养物 |
| JP4268209B2 (ja) * | 2005-07-20 | 2009-05-27 | ソウル ナショナル ユニバーシティ インダストリー ファウンデーション | 子宮内膜細胞を用いた造血幹細胞または前駆細胞の培養及び増殖方法 |
| EP1957633B1 (en) | 2005-10-13 | 2013-12-18 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| EP4223769A3 (en) | 2005-12-13 | 2023-11-01 | Kyoto University | Nuclear reprogramming factor |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| WO2007079184A2 (en) | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| EP2471903B1 (en) | 2005-12-29 | 2018-02-14 | Anthrogenesis Corporation | Placental stem cell populations |
| WO2007121443A2 (en) * | 2006-04-17 | 2007-10-25 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
| WO2008026198A2 (en) * | 2006-08-28 | 2008-03-06 | Yeda Research And Development Co. Ltd. | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns |
| US20080108044A1 (en) * | 2006-11-08 | 2008-05-08 | Deepika Rajesh | In vitro differentiation of hematopoietic cells from primate embryonic stem cells |
| US9005964B2 (en) * | 2006-11-24 | 2015-04-14 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
| US7883698B2 (en) * | 2007-01-17 | 2011-02-08 | Maria Michejda | Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use |
| PL2120977T3 (pl) | 2007-02-12 | 2013-12-31 | Anthrogenesis Corp | Leczenie chorób zapalnych z zastosowaniem łożyskowych komórek macierzystych |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| WO2008156708A2 (en) * | 2007-06-15 | 2008-12-24 | Massachusetts Institute Of Technology | Methods and compositions for enhanced differentiation from embryonic stem cells |
| WO2009015343A2 (en) * | 2007-07-25 | 2009-01-29 | Bioe, Inc. | Differentiation of multi-lineage progenitor cells to chondrocytes |
| US8263065B2 (en) | 2007-09-28 | 2012-09-11 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
| AU2008286249B2 (en) | 2007-12-10 | 2013-10-10 | Kyoto University | Efficient method for nuclear reprogramming |
| KR101598867B1 (ko) | 2008-04-30 | 2016-03-03 | 산바이오 인코포레이티드 | Ｄｎａ 메틸화에 변형을 가진 신경 재생 세포 |
| US20100279404A1 (en) | 2008-05-02 | 2010-11-04 | Shinya Yamanaka | Method of nuclear reprogramming |
| EP2294187A2 (en) * | 2008-05-21 | 2011-03-16 | BioE LLC | Differentiation of multi-lineage progenitor cells to pancreatic cells |
| DK2329012T3 (da) | 2008-08-20 | 2020-08-24 | Celularity Inc | Behandling af slagtilfælde under anvendelse af isolerede placentaceller |
| EP3172963B1 (en) | 2008-08-20 | 2019-02-06 | Celularity, Inc. | Improved cell composition and methods of making the same |
| DK2331109T3 (da) | 2008-08-22 | 2013-09-08 | Anthrogenesis Corp | Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer |
| RU2562154C2 (ru) | 2008-11-19 | 2015-09-10 | Антродженезис Корпорейшн | Амниотические адгезивные клетки |
| US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
| US9290737B2 (en) | 2009-02-24 | 2016-03-22 | Kanazawa Medical University | Method for enucleating nucleated erythrocyte, and enucleation inducer |
| WO2011005326A1 (en) | 2009-07-09 | 2011-01-13 | Massachusetts Institute Of Technology | Methods and compositions for increased safety of stem cell-derived populations |
| EP2462230B1 (en) | 2009-08-03 | 2015-07-15 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
| JP5902092B2 (ja) | 2009-10-19 | 2016-04-13 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 心筋細胞の生成 |
| KR20120115602A (ko) | 2010-01-26 | 2012-10-18 | 안트로제네시스 코포레이션 | 태반 줄기 세포를 사용한 골 관련 암의 치료 |
| PT2556145T (pt) | 2010-04-07 | 2016-10-25 | Anthrogenesis Corp | Angiogénese usando células estaminais placentárias |
| EP2555783A1 (en) | 2010-04-08 | 2013-02-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
| US20110312001A1 (en) | 2010-06-15 | 2011-12-22 | Emile Nuwaysir | Compendium of ready-built stem cell models for interrogation of biological response |
| KR20230096132A (ko) | 2010-07-13 | 2023-06-29 | 셀룰래리티 인코포레이티드 | 천연 킬러 세포의 생성 방법 |
| EP2601289B1 (en) | 2010-08-04 | 2017-07-12 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
| US9057734B2 (en) | 2010-08-23 | 2015-06-16 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
| US9677042B2 (en) | 2010-10-08 | 2017-06-13 | Terumo Bct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
| EP2630232A4 (en) | 2010-10-22 | 2014-04-02 | Biotime Inc | METHOD FOR MODIFYING TRANSCRIPTIONAL REGULATORY NETWORKS IN STEM CELLS |
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| US9700596B2 (en) | 2011-03-04 | 2017-07-11 | The Regents Of The University Of California | Locally released growth factors to mediate motor recovery after stroke |
| EP2691512B1 (en) | 2011-03-29 | 2019-05-01 | Asterias Biotherapeutics, Inc. | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
| US8785190B2 (en) | 2011-04-06 | 2014-07-22 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
| US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
| WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
| US20130058905A1 (en) | 2011-08-23 | 2013-03-07 | Igor Slukvin | Angiohematopoietic Progenitor Cells |
| US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| EP2594295A1 (en) | 2011-11-16 | 2013-05-22 | Servicio Andaluz De Salud | Nerve implants based on a compacted biomaterial containing cells |
| US9447378B2 (en) | 2012-04-27 | 2016-09-20 | Massachusetts Institute Of Technology | Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes |
| JP5432322B2 (ja) | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液 |
| AU2013237760A1 (en) | 2012-10-08 | 2014-04-24 | Biotime, Inc. | Differentiated progeny of clonal progenitor cell lines |
| JP2016506968A (ja) | 2013-02-05 | 2016-03-07 | アントフロゲネシス コーポレーション | 胎盤由来のナチュラルキラー細胞 |
| EP2987852A4 (en) | 2013-04-17 | 2016-09-07 | Nissan Chemical Ind Ltd | MEDIA COMPOSITION AND METHOD FOR THE PRODUCTION OF ERYTHROCYTES THEREWITH |
| EP3888640B1 (en) | 2013-06-05 | 2025-09-17 | Reverse Bioengineering, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| WO2014201431A1 (en) | 2013-06-14 | 2014-12-18 | Massachusetts Institute Of Technology | Articles and methods for stem cell differentiation |
| SG11201510045TA (en) | 2013-06-28 | 2016-01-28 | Otsuka Pharma Co Ltd | Trehalose and dextran-containing solution for transplanting mammalian cells |
| EP3068867B1 (en) | 2013-11-16 | 2018-04-18 | Terumo BCT, Inc. | Expanding cells in a bioreactor |
| CN103740642A (zh) * | 2014-01-28 | 2014-04-23 | 娄彩玲 | 一种生产人红细胞的方法 |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| CN106232800B (zh) | 2014-03-25 | 2020-07-03 | 泰尔茂比司特公司 | 介质的被动替代 |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| EP3198006B1 (en) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Scheduled feed |
| US11214772B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for retinal tissue |
| US10286009B2 (en) * | 2015-05-16 | 2019-05-14 | Asterias Biotherapeutics, Inc. | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| CA2997528C (en) | 2015-09-08 | 2024-02-13 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
| CA3202332A1 (en) | 2015-12-07 | 2017-06-15 | Agex Therapeutics, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells |
| EP3423158B1 (en) | 2016-02-24 | 2023-11-15 | The Rockefeller University | Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof |
| WO2017173064A1 (en) | 2016-03-30 | 2017-10-05 | Asterias Biotherapeutics, Inc. | Oligodendrocyte progenitor cell compositions |
| CN109415696A (zh) | 2016-05-25 | 2019-03-01 | 泰尔茂比司特公司 | 细胞扩增 |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| WO2018084228A1 (ja) | 2016-11-04 | 2018-05-11 | 国立大学法人東京大学 | 動物細胞又は動物組織の凍結保存用溶液、凍結物、及び凍結保存方法 |
| MY199613A (en) | 2016-11-25 | 2023-11-09 | Riken | Cell population for transplantation and method for producing same |
| CA3046169C (en) | 2016-12-14 | 2022-08-16 | Otsuka Pharmaceutical Factory, Inc. | Mammalian cell cryopreservation liquid |
| JP7007686B2 (ja) | 2017-03-08 | 2022-01-25 | 大日本住友製薬株式会社 | 網膜色素上皮細胞の製造方法 |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| WO2018184028A2 (en) | 2017-03-31 | 2018-10-04 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| WO2019017492A1 (ja) | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 連続的な上皮を含む網膜組織の成熟化方法 |
| EP3656846A4 (en) | 2017-07-20 | 2021-04-21 | Riken | Method for preserving neural tissue |
| CN111164205B (zh) | 2017-09-08 | 2024-05-17 | 国立研究开发法人理化学研究所 | 包含视网膜组织的细胞聚集体及其制造方法 |
| JP7360583B2 (ja) | 2017-09-14 | 2023-10-13 | 国立研究開発法人理化学研究所 | 網膜組織の製造方法 |
| EP3683304A4 (en) | 2017-09-14 | 2021-06-09 | Riken | METHOD OF REINFORCEMENT OF PIPE PHOTO RECEPTORS OR ROD PHOTO RECEPTORS WITH A DORSALIZATION SIGNAL TRANSMITTER OR VENTRALIZATION SIGNAL TRANSMITTER |
| CA3083344A1 (en) | 2017-11-24 | 2019-05-31 | Sumitomo Chemical Company, Limited | Production method for cell mass including neural cells/tissue and non-neural epithelial tissue, and cell mass from same |
| CA3083864A1 (en) | 2017-11-24 | 2019-05-31 | Sumitomo Chemical Company, Limited | Method for producing cell mass including pituitary tissue, and cell mass thereof |
| CA3096870A1 (en) | 2018-02-19 | 2019-08-22 | Sumitomo Dainippon Pharma Co., Ltd. | Cell aggregate, mixture of cell aggregates, and method for preparing same |
| WO2020039732A1 (ja) | 2018-08-24 | 2020-02-27 | 住友化学株式会社 | 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法 |
| US12365872B2 (en) | 2018-09-19 | 2025-07-22 | Lineage Cell Therapeutics, Inc. | Methods for differentiating pluripotent stem cells in dynamic suspension culture |
| KR20210045443A (ko) | 2018-09-28 | 2021-04-26 | 가부시기가이샤오오쓰까세이야꾸고오죠오 | 아카보즈 또는 스타키오스를 포함하는 포유동물 세포 보존용 액 |
| US20220010271A1 (en) | 2018-11-15 | 2022-01-13 | Jsr Corporation | Method for producing brain organoids |
| SG11202106642YA (en) | 2018-12-20 | 2021-07-29 | Sumitomo Chemical Co | Embryonic erythroblast-containing cell population and method for producing same, cell culture composition, and compound test method |
| EP3903789A4 (en) | 2018-12-28 | 2022-10-05 | Riken | THERAPEUTIC MEDICINE FOR A DISEASE INVOLVED IN DISORDERS IN CELLS OF THE RETINAL SYSTEM OR RETINAL TISSUE |
| EP3914264A4 (en) | 2019-01-23 | 2022-11-23 | Asterias Biotherapeutics, Inc. | OLIGODENDROCYTE PROGENITOR CELLS DERIVED FROM THE BACK FROM HUMAN PLURIPOTENT STEM CELLS |
| MY206063A (en) | 2019-03-13 | 2024-11-27 | Riken | Method for evaluating quality of transplant neural retina, and transplant neural retina sheet |
| JP7553924B2 (ja) | 2019-04-26 | 2024-09-19 | 国立研究開発法人理化学研究所 | 神経網膜と網膜色素上皮細胞とハイドロゲルとを含む複合体及びその製造方法 |
| CN113728089A (zh) | 2019-04-26 | 2021-11-30 | 株式会社大塚制药工场 | 含海藻糖的哺乳动物细胞保存用液 |
| KR20220052946A (ko) | 2019-09-06 | 2022-04-28 | 각고호우징 게이오기주크 | 글리아 전구 세포를 포함하는 세포 응집체의 제조 방법 |
| US20220408717A1 (en) | 2019-11-20 | 2022-12-29 | Sumitomo Pharma Co., Ltd. | Method for freezing cell aggregates |
| IL293137A (en) | 2019-11-20 | 2022-07-01 | Sumitomo Pharma Co Ltd | Method for freezing neural cells |
| US20230310614A1 (en) | 2020-09-11 | 2023-10-05 | Sumitomo Pharma Co., Ltd. | Medium for Tissue for Transplantation |
| CA3194226A1 (en) | 2020-09-11 | 2022-03-17 | Riken | Complex containing neural retina-containing cell aggregates and matrix, and method for manufacturing same |
| EP4306634A4 (en) | 2021-03-09 | 2025-03-26 | Riken | METHOD FOR PRODUCING HYPOIMMUNOGENIC RETINAL PIGMENT EPITHELIAL CELLS |
| JP7705950B2 (ja) | 2021-03-23 | 2025-07-10 | テルモ ビーシーティー、インコーポレーテッド | 細胞を増殖する方法 |
| CN117769591A (zh) | 2021-06-17 | 2024-03-26 | 国立大学法人京都大学 | 源自人多能干细胞的大脑皮质细胞制剂的制造方法 |
| KR20240056604A (ko) | 2021-09-13 | 2024-04-30 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 수임 심장 전구세포의 제조 방법 |
| WO2023049826A1 (en) | 2021-09-23 | 2023-03-30 | President And Fellows Of Harvard College | Genetically encoded voltage indicators and uses thereof |
| EP4410963A4 (en) | 2021-09-30 | 2025-10-08 | Sumitomo Chemical Co | METHOD FOR PRODUCING A CELL MASS COMPRISING A PITUITARY TISSUE AND CELL MASS |
| TW202330905A (zh) | 2021-09-30 | 2023-08-01 | 日商住友製藥股份有限公司 | 包含腦下垂體激素產生細胞之細胞凝集體及其製造方法 |
| CA3238664A1 (en) | 2021-11-19 | 2023-05-25 | Riken | Production method for sheet-like retinal tissue |
| CN118475685A (zh) | 2021-12-27 | 2024-08-09 | 住友制药株式会社 | 神经嵴细胞的培养方法及制造方法 |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| CA3254454A1 (en) | 2022-03-16 | 2025-03-04 | Racthera Co., Ltd. | METHOD OF TRANSPLANTATION |
| WO2023199641A1 (ja) | 2022-04-12 | 2023-10-19 | 株式会社大塚製薬工場 | 哺乳動物細胞凍結保存液 |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| EP4594471A1 (en) | 2022-09-30 | 2025-08-06 | Fujifilm Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
| JPWO2024172043A1 (enExample) | 2023-02-14 | 2024-08-22 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635386A (en) * | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
| CZ307995A3 (en) * | 1993-05-24 | 1996-10-16 | Immunex Corp | Ligands for flt3 receptors |
| US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| CA2262817A1 (en) | 1996-08-19 | 1998-02-26 | James Robl | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
| US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
-
1999
- 1999-11-08 US US09/435,578 patent/US6280718B1/en not_active Expired - Lifetime
-
2000
- 2000-08-25 CN CNB008153264A patent/CN1228443C/zh not_active Expired - Lifetime
- 2000-08-25 CA CA002390281A patent/CA2390281C/en not_active Expired - Lifetime
- 2000-08-25 IL IL14938700A patent/IL149387A0/xx active IP Right Grant
- 2000-08-25 EP EP00957842A patent/EP1228194A1/en not_active Withdrawn
- 2000-08-25 KR KR1020027005890A patent/KR20030022766A/ko not_active Ceased
- 2000-08-25 BR BR0015374-5A patent/BR0015374A/pt not_active Application Discontinuation
- 2000-08-25 AU AU69404/00A patent/AU784928B2/en not_active Expired
- 2000-08-25 JP JP2001537473A patent/JP2003513664A/ja active Pending
- 2000-08-25 WO PCT/US2000/023469 patent/WO2001034776A1/en not_active Ceased
- 2000-08-25 KR KR1020077008013A patent/KR20070047850A/ko not_active Ceased
-
2001
- 2001-08-27 US US09/940,175 patent/US6613568B2/en not_active Expired - Lifetime
-
2002
- 2002-04-28 IL IL149387A patent/IL149387A/en unknown
- 2002-05-03 SE SE0201328A patent/SE526490C2/sv unknown
- 2002-05-06 IS IS6373A patent/IS6373A/is unknown
- 2002-05-07 NO NO20022180A patent/NO20022180L/no not_active Application Discontinuation
-
2003
- 2003-08-29 US US10/652,468 patent/US20040043484A1/en not_active Abandoned
-
2009
- 2009-10-01 JP JP2009229464A patent/JP2010042011A/ja active Pending
-
2013
- 2013-10-07 JP JP2013210318A patent/JP2014000096A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SE0201328D0 (sv) | 2002-05-03 |
| IS6373A (is) | 2002-05-06 |
| KR20070047850A (ko) | 2007-05-07 |
| AU784928B2 (en) | 2006-07-27 |
| JP2010042011A (ja) | 2010-02-25 |
| KR20030022766A (ko) | 2003-03-17 |
| EP1228194A1 (en) | 2002-08-07 |
| IL149387A0 (en) | 2002-11-10 |
| US6613568B2 (en) | 2003-09-02 |
| IL149387A (en) | 2008-08-07 |
| NO20022180L (no) | 2002-06-03 |
| US20020015694A1 (en) | 2002-02-07 |
| CA2390281C (en) | 2005-10-25 |
| US20040043484A1 (en) | 2004-03-04 |
| NO20022180D0 (no) | 2002-05-07 |
| AU6940400A (en) | 2001-06-06 |
| SE526490C2 (sv) | 2005-09-27 |
| CN1387565A (zh) | 2002-12-25 |
| WO2001034776A1 (en) | 2001-05-17 |
| US6280718B1 (en) | 2001-08-28 |
| BR0015374A (pt) | 2002-12-24 |
| CN1228443C (zh) | 2005-11-23 |
| CA2390281A1 (en) | 2001-05-17 |
| SE0201328L (sv) | 2002-07-05 |
| JP2014000096A (ja) | 2014-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003513664A (ja) | ヒト胚性幹細胞の造血分化 | |
| EP1458854B1 (en) | Cellular compositions and methods of making and using them | |
| JP4146802B2 (ja) | 単球を起源に持つ、脱分化したプログラム可能な幹細胞およびそれらの製造と使用 | |
| US9399758B2 (en) | SSEA3(+) pluripotent stem cell that can be isolated from body tissue | |
| CN110997904B (zh) | 改进造血移植物的方法 | |
| US20230374458A1 (en) | Compositions and methods for generating human yolk sac-like hematopoietic cells | |
| JP2002532087A (ja) | 初期のｃｄ３４＋ｃｄ３８−骨髄幹細胞の増大のためのヒト脳内皮細胞及び増殖培地並びに方法 | |
| KR20080015033A (ko) | 배아 줄기 세포로부터 가지 세포를 형성하는 방법 | |
| US20050221482A1 (en) | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof | |
| CN113557296A (zh) | 造血干细胞的扩增 | |
| JP2002543829A (ja) | 哺乳動物造血幹細胞のｅｘｖｉｖｏでの増殖 | |
| KR20120006386A (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
| JP2025131844A (ja) | 多能性幹細胞由来の造血性内皮細胞からのリンパ球系細胞の分化方法 | |
| Kelley et al. | Collection and Expansion of Stem Cells | |
| JPH11103856A (ja) | 造血幹細胞の増殖促進剤 | |
| JPWO1999003980A1 (ja) | Ａｇｍ領域由来ストローマ細胞 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070824 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070824 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090309 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090508 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090508 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091001 |